• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • COVID-19
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • Artificial Intelligence
    • Blockchain
    • Mobile Health
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

LabCorp Launches Fully Integrated Clinical Trial Platform to Streamline Drug Development Process

by Fred Pennic 10/20/2020 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
LabCorp Launches Fully Integrated Clinical Trial Platform to Streamline Drug Development Process

What You Should Know:

– LabCorp launches fully integrated clinical trial platform to streamline the drug development process featuring

– The new clinical trial platform will deliver dramatic reductions in patient and study site administrative tasks, improve trial resiliency, and maintain study continuity through the use of the company’s data, technology, and direct-to-patient outreach capabilities.  


Global life sciences company LabCorp today announced new capabilities that will transform the clinical trial experience with the goal of streamlining the drug development process. This transformation will enable LabCorp’s drug development business, Covance, a global leader in decentralized clinical trials (DCTs), to quickly and efficiently connect patients to clinical trials, which will allow for better access to potential drugs, vaccines, and medical devices.

Additionally, the seamless, tech-enabled, patient-centric capabilities will provide a better clinical trial experience for patients, and biopharmaceutical and medical device customers.

LabCorp now offers a comprehensive and fully-integrated patient, site, and customer experience for DCTs. The clinical trial platform will deliver dramatic reductions in patient and study site administrative tasks, improve trial resiliency, and maintain study continuity through the use of the company’s data, technology, and direct-to-patient outreach capabilities.

These results are made possible through the recent acquisitions of GlobalCare, a global mobile nursing and ambulant care organization that provides services in more than 65 countries, and snapIoT, a global medical technology company that provides a digitized clinical platform (mClinical) that supports remote participation in clinical trials.

Streamlining the Drug Development Process

The company’s digitized clinical trials solution provides data interoperability across the trial delivery continuum and optimizes the site workflow by reducing the number of disparate tools and platforms used during clinical trials to one integrated solution.

This solution could include functions such as eConsent, ePRO, and eCOA; telehealth and connected devices to improve data collection; and digitization of mobile nursing visits and sample collections. This results in faster enrollment, easier engagement, more efficient studies, and quicker data locks.

Improved Clinical Trial Design

A hallmark of this new approach is that LabCorp can now speed up trial design and implementation while de-risking the execution process by providing complete, integrated solutions from a single partner.

LabCorp’s services include improved trial design that takes into account its Voice of the Patient and direct-to-patient recruitment strategies; virtual offerings, such as:

– telemedicine to enable more efficient doctor-patient interactions; access to LabCorp’s approximately 2,000 patient service centers;

– mobile phlebotomy and nursing services

– other clinical trial services the company offers.

All of these services and technologies are supported by a high-touch patient contact center and can be delivered by one provider, LabCorp, and its drug development business, Covance.

“By deploying protocol-specific, tech-enabled solutions, we are providing patient-centric trial experiences,” said Dr. Paul Kirchgraber, CEO, LabCorp’s drug development business, Covance. “In addition to reducing the burden on patients, our approach improves data quality and provides operational efficiencies that will benefit our biopharmaceutical and medical device customers.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: LabCorp

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Knowledge Hub

 How Top Health Plans Use AI to Save Money and Work Smarter How Top Health Plans Use AI to Save Money and Work Smarter

 How to Build Hybrid Care Models Around Remote Patient Monitoring How to Build Hybrid Care Models Around Remote Patient Monitoring

Trending

Metriport Launches Open-Source API to Instantly Pull Medical Records from Any EHR

Metriport Launches Open-Source API to Instantly Pull Medical Records from Any EHR

Nearly Half Of Consumers Report Their Healing has Been Directly Impacted by Difficulty Paying Medical Bills

Consumers Cite Healthcare Affordability as Biggest Concern to Paying Medical Bills

Mayo Clinic, GE HealthCare, Partner on Medical Imaging and Theranostics Innovation

Roundups: 16 Recent Strategic Digital Health Partnerships

How Telehealth Can Combat Clinician Burnout

How Telehealth Can Combat Clinician Burnout

Q/A: DocStation CEO Shares How AI Will Help Pharmacies Use the DIR Fee Changes to Their Advantage

Q/A: DocStation CEO Shares How AI Will Help Pharmacies Use the DIR Fee Changes to Their Advantage

Debunking Myths About Virtual Care to Drive Health Equity

Debunking 3 Myths About Virtual Care to Drive Health Equity

Provider AI Strategy Moves From The IT Dept. To The C-Suite

Notable Launches ChatGPT-Like Assistant for Patients

Notable Launches ChatGPT-Like Assistant for Patients

Intermountain to Replace Cerner with Epic Enterprise EHR by 2025

Intermountain to Replace Cerner with Epic Enterprise EHR by 2025

M&A: PE Firm Acquires NextGen Healthcare EHR for $1.8B

M&A: NextGen Healthcare EHR Acquired by PE Firm for $1.8B

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • 2023 Editorial Calendar
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2023. HIT Consultant Media. All Rights Reserved. Privacy Policy |